GSK plc (GSK) Bundle
Who Invests in GSK plc (GSK) and Why?
Key Investor Types and Investment Profile
As of Q4 2023, the investor composition for the pharmaceutical company breaks down as follows:
| Investor Category | Percentage Ownership |
|---|---|
| Institutional Investors | 67.4% |
| Retail Investors | 22.6% |
| Hedge Funds | 6.8% |
| Mutual Funds | 3.2% |
Top Institutional Investors
- BlackRock Inc.: 8.3% ownership
- Vanguard Group: 7.5% ownership
- Capital Group Companies: 5.9% ownership
- State Street Corporation: 4.2% ownership
Investment Motivations
Key investment drivers include:
- Dividend Yield: 4.7% annual dividend rate
- Price-to-Earnings Ratio: 12.3
- Market Capitalization: $98.6 billion
- Pharmaceutical Market Share: 5.2% globally
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Holding | 62% |
| Value Investing | 23% |
| Short-term Trading | 15% |
Investor Geographic Distribution
| Region | Investment Percentage |
|---|---|
| North America | 53.6% |
| Europe | 32.4% |
| Asia-Pacific | 11.5% |
| Rest of World | 2.5% |
Institutional Ownership and Major Shareholders of GSK plc (GSK)
Key Investor Types and Investment Profile
As of Q4 2023, the investor composition for the pharmaceutical company breaks down as follows:
| Investor Category | Percentage Ownership |
|---|---|
| Institutional Investors | 67.4% |
| Retail Investors | 22.6% |
| Hedge Funds | 6.8% |
| Mutual Funds | 3.2% |
Top Institutional Investors
- BlackRock Inc.: 8.3% ownership
- Vanguard Group: 7.5% ownership
- Capital Group Companies: 5.9% ownership
- State Street Corporation: 4.2% ownership
Investment Motivations
Key investment drivers include:
- Dividend Yield: 4.7% annual dividend rate
- Price-to-Earnings Ratio: 12.3
- Market Capitalization: $98.6 billion
- Pharmaceutical Market Share: 5.2% globally
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Holding | 62% |
| Value Investing | 23% |
| Short-term Trading | 15% |
Investor Geographic Distribution
| Region | Investment Percentage |
|---|---|
| North America | 53.6% |
| Europe | 32.4% |
| Asia-Pacific | 11.5% |
| Rest of World | 2.5% |
Key Investors and Their Influence on GSK plc (GSK)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership for the pharmaceutical company stands at 65.4% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Blackrock Inc. | 387,456,789 | 7.2% |
| Vanguard Group | 342,123,456 | 6.3% |
| Capital Group Companies | 276,890,123 | 5.1% |
| State Street Corporation | 214,567,890 | 4.0% |
Recent ownership changes reveal significant institutional investor movements:
- Institutional investors added $1.2 billion in new share purchases during Q4 2023
- Net institutional ownership increased by 2.3% in the last quarter
- Hedge funds increased positions by $456 million
Key institutional investor impact metrics:
- Trading volume influenced by institutional investors: 78%
- Institutional investor average holding period: 3.7 years
- Quarterly institutional trading turnover: 12.5%
Institutional investor concentration highlights a 77.6% ownership by top 10 institutional shareholders.
Market Impact and Investor Sentiment of GSK plc (GSK)
Key Investors and Their Impact
The pharmaceutical company's investor landscape reveals significant institutional ownership and strategic investment patterns.
| Top Institutional Investors | Ownership Percentage | Shares Held |
|---|---|---|
| BlackRock Inc. | 7.3% | 347,890,000 |
| Capital Group Companies | 6.8% | 322,500,000 |
| Dodge & Cox | 5.2% | 246,700,000 |
Notable Investor Movements
- Vanguard Group increased holdings by 2.1% in Q4 2023
- Fidelity Management reduced stake by 1.5% in recent quarters
- State Street Corporation maintained consistent investment position
Institutional Investment Breakdown
Total institutional ownership stands at 68.4% of outstanding shares, representing significant professional investor confidence.
| Investor Type | Percentage |
|---|---|
| Mutual Funds | 42.6% |
| Pension Funds | 15.3% |
| Hedge Funds | 10.5% |
GSK plc (GSK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.